FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2607145250> ?p ?o ?g. }

• W2607145250 endingPage "423" @default.
• W2607145250 startingPage "415" @default.
• W2607145250 abstract "<b><i>Background:</i></b> Gastroesophageal reflux disease is a potential risk factor for idiopathic pulmonary fibrosis (IPF) progression; however, the impact of antacid therapy (AAT) is under debate. <b><i>Objective:</i></b> To evaluate the effect of AAT on IPF progression in pirfenidone-treated patients. <b><i>Methods:</i></b> This post hoc analysis included patients with IPF who received pirfenidone in 3 trials (CAPACITY [PIPF-004/PIPF-006] and ASCEND [PIPF-016]). Pulmonary function, exercise tolerance, survival, hospitalizations, and adverse events (AEs) over 52 weeks were analyzed by baseline AAT use. Disease progression was defined as a decrease in forced vital capacity (FVC) of ≥10%, a decrease in 6-min walking distance of ≥50 m, or death over 1 year. <b><i>Results:</i></b> Of 623 patients, 44% received AAT. No significant differences were found at 52 weeks (AAT versus non-AAT, respectively) in disease progression (24.9 vs. 30.6%; <i>p</i> = 0.12), all-cause mortality rate (2.9 vs. 4.0%; <i>p</i> = 0.47), IPF-related mortality rate (1.1 vs. 2.0%; <i>p</i> = 0.37), all-cause hospitalization rate (16.1 vs. 18.3%; <i>p</i> = 0.48), or mean change in percent FVC (-2.7 vs. -3.1%; <i>p</i> = 0.44). A relative, but not absolute, FVC decline of ≥10% favored AAT (15 vs. 22%; <i>p</i> = 0.03). Severe gastrointestinal AEs (3.7 vs. 0.9%; <i>p</i> = 0.015) and severe pulmonary infections (3.7 vs. 1.1%; <i>p</i> = 0.035) were more frequent with AAT. <b><i>Conclusions:</i></b> AAT and pirfenidone had outcomes comparable to those of pirfenidone alone in patients with IPF, underscoring the need for prospective trials to elucidate the role of AAT with or without antifibrotic drugs as a treatment for IPF." @default.
• W2607145250 created "2017-04-28" @default.
• W2607145250 creator A5006969715 @default.
• W2607145250 creator A5010568573 @default.
• W2607145250 creator A5014353115 @default.
• W2607145250 creator A5038615410 @default.
• W2607145250 creator A5043303194 @default.
• W2607145250 creator A5058325633 @default.
• W2607145250 creator A5059136692 @default.
• W2607145250 creator A5059849214 @default.
• W2607145250 creator A5065730561 @default.
• W2607145250 creator A5079519206 @default.
• W2607145250 creator A5090203143 @default.
• W2607145250 date "2017-01-01" @default.
• W2607145250 modified "2023-10-10" @default.
• W2607145250 title "Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone" @default.
• W2607145250 cites W1938547050 @default.
• W2607145250 cites W1969841863 @default.
• W2607145250 cites W1992597933 @default.
• W2607145250 cites W1998274991 @default.
• W2607145250 cites W2009185669 @default.
• W2607145250 cites W2015683287 @default.
• W2607145250 cites W2045686994 @default.
• W2607145250 cites W2057292199 @default.
• W2607145250 cites W2071521423 @default.
• W2607145250 cites W2105872263 @default.
• W2607145250 cites W2112316706 @default.
• W2607145250 cites W2115484301 @default.
• W2607145250 cites W2123641148 @default.
• W2607145250 cites W2123700925 @default.
• W2607145250 cites W2126123339 @default.
• W2607145250 cites W2129514617 @default.
• W2607145250 cites W2132594366 @default.
• W2607145250 cites W2138871107 @default.
• W2607145250 cites W2144469870 @default.
• W2607145250 cites W2152237318 @default.
• W2607145250 cites W2167383172 @default.
• W2607145250 cites W2168666423 @default.
• W2607145250 cites W2194057804 @default.
• W2607145250 cites W2208096782 @default.
• W2607145250 cites W2228628153 @default.
• W2607145250 cites W2252411692 @default.
• W2607145250 cites W2257989762 @default.
• W2607145250 cites W2314545164 @default.
• W2607145250 cites W2328539250 @default.
• W2607145250 cites W2397094883 @default.
• W2607145250 cites W2516961983 @default.
• W2607145250 cites W2517037725 @default.
• W2607145250 cites W2523522924 @default.
• W2607145250 doi "https://doi.org/10.1159/000468546" @default.
• W2607145250 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5452370" @default.
• W2607145250 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28399537" @default.
• W2607145250 hasPublicationYear "2017" @default.
• W2607145250 type Work @default.
• W2607145250 sameAs 2607145250 @default.
• W2607145250 citedByCount "56" @default.
• W2607145250 countsByYear W26071452502017 @default.
• W2607145250 countsByYear W26071452502018 @default.
• W2607145250 countsByYear W26071452502019 @default.
• W2607145250 countsByYear W26071452502020 @default.
• W2607145250 countsByYear W26071452502021 @default.
• W2607145250 countsByYear W26071452502022 @default.
• W2607145250 countsByYear W26071452502023 @default.
• W2607145250 crossrefType "journal-article" @default.
• W2607145250 hasAuthorship W2607145250A5006969715 @default.
• W2607145250 hasAuthorship W2607145250A5010568573 @default.
• W2607145250 hasAuthorship W2607145250A5014353115 @default.
• W2607145250 hasAuthorship W2607145250A5038615410 @default.
• W2607145250 hasAuthorship W2607145250A5043303194 @default.
• W2607145250 hasAuthorship W2607145250A5058325633 @default.
• W2607145250 hasAuthorship W2607145250A5059136692 @default.
• W2607145250 hasAuthorship W2607145250A5059849214 @default.
• W2607145250 hasAuthorship W2607145250A5065730561 @default.
• W2607145250 hasAuthorship W2607145250A5079519206 @default.
• W2607145250 hasAuthorship W2607145250A5090203143 @default.
• W2607145250 hasBestOaLocation W26071452501 @default.
• W2607145250 hasConcept C126322002 @default.
• W2607145250 hasConcept C165637977 @default.
• W2607145250 hasConcept C2777714996 @default.
• W2607145250 hasConcept C2778341716 @default.
• W2607145250 hasConcept C2779832356 @default.
• W2607145250 hasConcept C3018587741 @default.
• W2607145250 hasConcept C55520419 @default.
• W2607145250 hasConcept C71924100 @default.
• W2607145250 hasConcept C75603125 @default.
• W2607145250 hasConcept C90924648 @default.
• W2607145250 hasConceptScore W2607145250C126322002 @default.
• W2607145250 hasConceptScore W2607145250C165637977 @default.
• W2607145250 hasConceptScore W2607145250C2777714996 @default.
• W2607145250 hasConceptScore W2607145250C2778341716 @default.
• W2607145250 hasConceptScore W2607145250C2779832356 @default.
• W2607145250 hasConceptScore W2607145250C3018587741 @default.
• W2607145250 hasConceptScore W2607145250C55520419 @default.
• W2607145250 hasConceptScore W2607145250C71924100 @default.
• W2607145250 hasConceptScore W2607145250C75603125 @default.
• W2607145250 hasConceptScore W2607145250C90924648 @default.
• W2607145250 hasIssue "6" @default.
• W2607145250 hasLocation W26071452501 @default.

• next